Abstract
Final results of the CALGB 90206 and AVOREN trials have failed to demonstrate an overall survival benefit for bevacizumab plus interferon compared to interferon monotherapy in patients with metastatic renal cell carcinoma. Progression-free survival or objective response rate might be more suitable primary end points in phase III trials.
MeSH terms
-
Carcinoma, Renal Cell / drug therapy
-
Carcinoma, Renal Cell / mortality*
-
Clinical Trials, Phase III as Topic / methods
-
Clinical Trials, Phase III as Topic / mortality
-
Disease-Free Survival
-
Drug Therapy, Combination / methods
-
Drug Therapy, Combination / mortality
-
Endpoint Determination / methods
-
Endpoint Determination / mortality*
-
Humans
-
Kidney Neoplasms / drug therapy
-
Kidney Neoplasms / mortality*
-
Survival Rate / trends